Pacira BioSciences, Inc. (PCRX) stock
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)
Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –
Pacira BioSciences enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Pacira BioSciences's enterprise value was $1.56B on Nov 11, 2026, against $1.14B a year earlier. Over the last 5 years it ranged from $289.84M to $2.76B, with a median of $1.20B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.56B | +25.9% |
| 2025 | Dec 31, 2025 | $1.24B | +198.9% |
| 2024 | Dec 31, 2024 | $415.62M | -68.8% |
| 2023 | Dec 29, 2023 | $1.33B | -7.7% |
| 2022 | Dec 30, 2022 | $1.44B | -27.4% |
| 2021 | Dec 31, 2021 | $1.99B | -3.6% |
| 2020 | Dec 31, 2020 | $2.06B | +26.9% |
| 2019 | Dec 31, 2019 | $1.62B | +17.6% |
| 2018 | Dec 31, 2018 | $1.38B | -11.4% |
| 2017 | Dec 29, 2017 | $1.56B | +49.4% |
| 2016 | Dec 30, 2016 | $1.04B | -61.0% |
| 2015 | Dec 31, 2015 | $2.67B | -12.1% |
| 2014 | Dec 31, 2014 | $3.04B | +65.0% |
| 2013 | Dec 31, 2013 | $1.84B | +251.1% |
| 2012 | Dec 31, 2012 | $525.46M | +282.3% |
| 2011 | Dec 30, 2011 | $137.44M | – |
See a number that looks wrong?